Metraipolis › archive › dc_201e85a4bca8
Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events — Europe PMC PMID:35143542
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/35143542
- DOI
- 10.1371/journal.pone.0263402
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-31T09:44:09.937Z
- SHA-256 of the archived text
5ffc814b979aee6af49028d8d546a4d46d31ec18908b00a0f76d80209638bd8e- Stable URL of this page
https://metraipolis.com/documento/dc_201e85a4bca8
How to cite
Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events — Europe PMC PMID:35143542 — Europe PMC (en), https://europepmc.org/article/MED/35143542 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_201e85a4bca8 (Metraipolis archive dc_201e85a4bca8, sha256 5ffc814b979aee6af49028d8d546a4d46d31ec18908b00a0f76d80209638bd8e)
BibTeX
@misc{dc201e85a4bca8,
title = {Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events — Europe PMC PMID:35143542},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/35143542},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_201e85a4bca8; sha256 5ffc814b979aee6af49028d8d546a4d46d31ec18908b00a0f76d80209638bd8e},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/35143542. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Biologics targeting PD-1, PD-L1, and CTLA-4 immune checkpoint proteins have been used in a variety of tumor types including small and non-small cell lung cancers, melanoma, and renal cell carcinoma. Their anti-tumor activity is achieved through amplifying components of the patient's own immune system to target immune response evading cancer cells. However, this unique mechanism of action causes a range of immune related adverse events, irAEs, that affect multiple physiological systems in the body. These irAEs, depending on severity, often cause suspension or discontinuation of therapy and, in rare cases, may lead to fatal outcomes. In this study we focused on pembrolizumab, a PD-1 inhibitor currently approved for multiple types of cancer. We analyzed over ten thousand adverse event reports from Keynote clinical trials of pembrolizumab for various cancer indications with or without co-occurring infections, and observed a statistically significant 80% increase in the risk of developing an irAE in subjects with infections. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-02-10). Identificativi: PMID 35143542 · PMCID PMC8830697 · DOI 10.1371/journal.pone.0263402. Descrittori MeSH principali: Antibodies, Monoclonal, Humanized. Pagina: https://europepmc.org/article/MED/35143542 — https://doi.org/10.1371/journal.pone.0263402. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-31T09:32:12.580Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.